Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.
Saved in:
| Title: | Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology. |
|---|---|
| Authors: | Schauer SP; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Toth B; Department of Data and Statistical Sciences, Immunology, Infectious Diseases, and Ophthalmology, Genentech Inc., South San Francisco, California, USA., Lee J; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Honigberg LA; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Ramakrishnan V; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA., Jiang J; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Kollmorgen G; Roche Diagnostics, GmbH, Penzberg, Germany., Bayfield A; Roche Diagnostics, GmbH, Penzberg, Germany., Wild N; Roche Diagnostics, GmbH, Penzberg, Germany., Hoffman J; Department of Translational Medicine, Operations Diagnostics Technology Innovation, Genentech Inc., South San Francisco, California, USA., Ceniceros R; Department of Early Clinical Development, Clinical Operations, Genentech Inc., South San Francisco, California, USA., Dolton M; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA., Bohórquez SMS; Department of Early Clinical Development, Clinical Imaging Group, Genentech Inc., South San Francisco, California, USA., Hoogenraad CC; Department of Neuroscience, Genentech Inc., South San Francisco, California, USA., Wildsmith KR; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Teng E; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA., Monteiro C; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA., Anania V; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Yeh FL; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA. |
| Source: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Dec; Vol. 20 (12), pp. 8855-8866. Date of Electronic Publication: 2024 Nov 08. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39513754 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Schauer+SP%22">Schauer SP</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Toth+B%22">Toth B</searchLink>; Department of Data and Statistical Sciences, Immunology, Infectious Diseases, and Ophthalmology, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Lee+J%22">Lee J</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Honigberg+LA%22">Honigberg LA</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ramakrishnan+V%22">Ramakrishnan V</searchLink>; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Jiang+J%22">Jiang J</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Kollmorgen+G%22">Kollmorgen G</searchLink>; Roche Diagnostics, GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Bayfield+A%22">Bayfield A</searchLink>; Roche Diagnostics, GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Wild+N%22">Wild N</searchLink>; Roche Diagnostics, GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Hoffman+J%22">Hoffman J</searchLink>; Department of Translational Medicine, Operations Diagnostics Technology Innovation, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ceniceros+R%22">Ceniceros R</searchLink>; Department of Early Clinical Development, Clinical Operations, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Dolton+M%22">Dolton M</searchLink>; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Bohórquez+SMS%22">Bohórquez SMS</searchLink>; Department of Early Clinical Development, Clinical Imaging Group, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Hoogenraad+CC%22">Hoogenraad CC</searchLink>; Department of Neuroscience, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Wildsmith+KR%22">Wildsmith KR</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Teng+E%22">Teng E</searchLink>; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Monteiro+C%22">Monteiro C</searchLink>; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Anania+V%22">Anania V</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Yeh+FL%22">Yeh FL</searchLink>; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101231978%22">Alzheimer's & dementia : the journal of the Alzheimer's Association</searchLink> [Alzheimers Dement] 2024 Dec; Vol. 20 (12), pp. 8855-8866. <i>Date of Electronic Publication: </i>2024 Nov 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons%2C+Ltd%22">John Wiley & Sons, Ltd </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101231978 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1552-5279 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215525260%22">15525260 </searchLink><i>NLM ISO Abbreviation: </i>Alzheimers Dement <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39513754 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/alz.14346 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 8855 Titles: – TitleFull: Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Schauer SP – PersonEntity: Name: NameFull: Toth B – PersonEntity: Name: NameFull: Lee J – PersonEntity: Name: NameFull: Honigberg LA – PersonEntity: Name: NameFull: Ramakrishnan V – PersonEntity: Name: NameFull: Jiang J – PersonEntity: Name: NameFull: Kollmorgen G – PersonEntity: Name: NameFull: Bayfield A – PersonEntity: Name: NameFull: Wild N – PersonEntity: Name: NameFull: Hoffman J – PersonEntity: Name: NameFull: Ceniceros R – PersonEntity: Name: NameFull: Dolton M – PersonEntity: Name: NameFull: Bohórquez SMS – PersonEntity: Name: NameFull: Hoogenraad CC – PersonEntity: Name: NameFull: Wildsmith KR – PersonEntity: Name: NameFull: Teng E – PersonEntity: Name: NameFull: Monteiro C – PersonEntity: Name: NameFull: Anania V – PersonEntity: Name: NameFull: Yeh FL IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2024 Dec Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1552-5279 Numbering: – Type: volume Value: 20 – Type: issue Value: 12 Titles: – TitleFull: Alzheimer's & dementia : the journal of the Alzheimer's Association Type: main |
| ResultId | 1 |